Structural insights into the function of type IB topoisomerases

Current Opinion in Structural Biology

Volumn 9, Issue 1, 1999, Pages 29-36

  Redinbo, Matthew R ^a   Champoux, James J ^a   Hol, Wim Gj ^a  

^a HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BACTERIAL ENZYME; CAMPTOTHECIN; DNA TOPOISOMERASE; IRINOTECAN; TOPOTECAN; VIRUS ENZYME;

CRYSTAL STRUCTURE; DNA PROTEIN COMPLEX; DNA STRAND BREAKAGE; DRUG MECHANISM; DRUG PROTEIN BINDING; ENZYME ACTIVE SITE; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN DNA BINDING; REVIEW; STEREOCHEMISTRY; VACCINIA VIRUS;

BACTERIA (MICROORGANISMS); EUKARYOTA; VACCINIA; VACCINIA VIRUS;

EID: 0032871803     PISSN: 0959440X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-440X(99)80005-0     Document Type: Article

References (40)

1. Wang JC DNA topoisomerases. Annu Rev Biochem. 65:1996;635-692.
2. Champoux JJ Domains of human topoisomerase I and associated functions. Prog Nucleic Acid Res Mol Biol. 60:1998;111-132.
3. Gupta M, Fujimori A, Pommier Y Eukaryotic DNA topoisomerases I. Biochim Biophys Acta. 1262:1995;1-14.
4. Li W, Wang JC Mammalian DNA topoisomerase IIIa is essential in early embryogenesis. Proc Natl Acad Sci USA. 5:1998;1010-1013.
5. Berger JM, Fass D, Wang JC, Harrison SC Structural similarities between topoisomerases that cleave one or both DNA strands. Proc Natl Acad Sci USA. 95:1998;7876-7881.
6. Lima CD, Wang JC, Mondragón A Three-dimensional structure of the 67K N-terminal fragment of E. coli DNA topoisomerase I. Nature. 367:1994;138-146.
7. Lue N, Sharma A, Mondragón A, Wang JC A 26 kDa yeast DNA topoisomerase I fragment: crystallographic structure and mechanistic implications. Structure. 3:1995;1315-1322.
8. Sharma A, Hanai R, Mondragón A Crystal structure of the amino-terminal fragment of vaccinia virus DNA topoisomerase I at 1.6 Å resolution. Structure. 2:1994;767-777.
9. Yu L, Zhu C-X, Tse-Dinh Y-C, Fesik SW Solution structure of the C-terminal single-stranded DNA-binding domain of Eschericia coli topoisomerase I. Biochemistry. 34:1995;7622-7628.
10. Redinbo MR, Stewart L, Kuhn P, Champoux JJ, Hol WGJ Crystal structures of human topoisomerase I in covalent and noncovalent complexes with DNA. Science. 279:1998;1504-1513. The authors solved the crystal structures of reconstituted forms of human topoisomerase I in both covalent and noncovalent complexes with double-stranded DNA. Structural similarity to the family of tyrosine recombinases is shown and a model for the binding of the anticancer drug camptothecin to the covalent complex of human topoisomerase I and DNA is proposed.
11. Stewart L, Redinbo MR, Qiu X, Hol WGJ, Champoux JJ A model for the mechanism of human topoisomerase I. Science. 279:1998;1534-1541. The crystal structure of an intact, 70 kDa form of human topoisomerase I in a noncovalent complex with double-stranded DNA is reported. A model for the mechanism of strand cleavage is proposed, as well as a 'controlled rotation' mechanism for the relaxation of superhelical tension by the enzyme.
12. Cheng C, Kussie P, Pavletich N, Shuman S Conservation of structure and mechanism between eukaryotic topoisomerase I and site-specific recombinases. Cell. 92:1998;841-850. The crystal structure of the catalytic core of the vaccinia virus topoisomerase (residues 81-314 of the 364 residue protein) reveals a structural similarity to the tyrosine recombinases and a shifting of the catalytic tyrosine 10 Å away from the other active site residues.
13. Stewart L, Ireton GC, Champoux JJ The domain organization of human topoisomerase I. J Biol Chem. 271:1996;7602-7608.
14. Stewart L, Ireton GC, Parker LH, Madden KR, Champoux JJ Biochemical and biophysical analyses of recombinant forms of human topisomerase I. J Biol Chem. 271:1996;7593-7601.
15. Bharti AK, Olson MOJ, Kufe DW, Rubin EH Identification of a nucleolin binding site in human topoisomerase I. J Biol Chem. 271:1996;1993-1997.
16. Simmons DT, Melendy T, Usher D, Stillman B Simian virus 40 large T antigen binds to topoisomerase I. Virology. 222:1996;365-374.
17. Pommier Y, Kohlhagen G, Wu C, Simmons DT Mammalian DNA topoisomerase I activity and poisoning by camptothecin are inhibitee by simian virus 40 large T antigen. Biochemistry. 37:1998;3813-3823.
18. Kretzschmar M, Meisterernst M, Roeder RG Identification of human DNA topoisomerase I as a cofactor for activator-dependent transcription by RNA polymerase II. Proc Natl Acad Sci USA. 90:1993;11508-11512.
19. Merino A, Madden KR, Lane WS, Champoux JJ, Reinberg D DNA topoisomerase I is involved in both repression and activation of transcription. Nature. 365:1993;227-232.
20. Shykind BM, Kim J, Stewart L, Champoux JJ, Sharp PA Topoisomerase I enhances TFIID-TFIIA complex assembly during activation of transcription. Genes Dev. 11:1997;397-407.
21. Stewart L, Ireton GC, Champoux JJ Reconstitution of human topoisomerase I by fragment complementation. J Mol Biol. 269:1997;355-372.
22. Kwon HJ, Tirumalai R, Landy A, Ellenberger T Flexibility in DNA recombination: structure of the lambda integrase catalytic core. Science. 276:1997;126-131. The crystal structure of the catalytic core of λ integrase reveals a shifting of the catalytic tyrosine 20 Å away from the remaining active site residues, suggesting that a rearrangement step is required prior to catalysis in this class of enzymes.
23. Subramanya HS, Arciszewska LK, Baker RA, Bird LE, Sherratt DJ, Wigley DB Crystal structure of the site-specific recombinase, XerD. EMBO J. 16:1997;5178-5187. The crystal structure of XerD recombinase from Escherichia coli suggests that only a minor rearrangement of the protein structure is required to prepare the active site for catalysis.
24. Been MD, Burgess RR, Champoux JJ Nucleotide sequence preference at rat liver and wheat germ type 1 DNA topoisomerase breakage sites in duplex SV40 DNA. Nucleic Acids Res. 12:1984;3097-3114.
25. Andersen AH, Gocke E, Bonven BJ, Nielsen OF, Westergaard O Topoisomerase I has a strong binding preference for a conserved hexadecameric sequence in the promoter region of the rRNA gene from Tetrahymena pyriformis. Nucleic Acids Res. 13:1985;1543-1557.
26. Sekiguchi J, Shuman S Identification of contacts between topisomerase I and its target DNA by site-specific photocrosslinking. EMBO J. 15:1996;3448-3457.
27. Sekiguchi J, Shuman S Mutational analysis of vaccinia virus topisomerase identifies residues involved in DNA binding. Nucleic Acids Res. 25:1997;3649-3656.
28. Berger JM, Gamblin SJ, Harrison SC, Wang JC Structure and mechanism of DNA topoisomerase II. Nature. 379:1996;225-232.
29. Guo F, Gopaul DN, Van Duyne GD Structure of Cre recombinase complexed with DNA in a site-specific recombination synapse. Nature. 389:1997;40-46. This paper describes the crystal structure of bacteriophage Cre recombinase arranged as an active tetramer about a site-specific DNA recombination synapse, with two of the four catalytic tyrosines forming covalent 3′ phosphotyrosine linkages with the DNA.
30. Sherratt DJ, Wigley DB Conserved themes but novel activities in recombinases and topoisomerases. Cell. 93:1998;149-152.
31. Wigley DB Teaching a new dog old tricks? Structure. 6:1998;543-548.
32. Hickman AB, Waninger S, Scocca JJ, Dyda F Molecular organizaton in site-specific recombination: the catalytic domain of bacteriophase HP1 integrase at 2.7 Å resolution. Cell. 89:1997;227-237. The crystal structure of the catalytic core (residues 165-337) of the bacteriophage HP1 integrase reveals a cluster of active site residues in close proximity and suggests that no rearrangement step is required prior to catalysis.
33. Wang H-K, Morris-Natschke SL, Lee K-H Recent advances in the discovery and development of topoisomerase inhibitors as antitumor agents. Med Res Rev. 17:1997;367-425.
34. Armand JP, Ducreux M, Mahjoubi M, Abigerges D, Bugat R, Chabot G, Herait P, de Forni M, Rougier P CPT-11 (irinotecan) in the treatment of colorectal cancer. Eur J Cancer. 31A:1995;1283-1287.
35. O'Reilly S, Rowinsky EK The clinical status of irinotecan (CPT-11), a novel water soluble camptothecin analogue. Crit Rev Oncol Hematol. 24:1996;47-70.
36. Dancey J, Eisenhauer EA Current perspectives on camptothecins in cancer treatment. Br J Cancer. 74:1996;327-338.
37. Hsiang YH, Hertzberg R, Hecht S, Liu LF Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem. 260:1985;14873-14878.
38. Abigerges D, Armand JP, Chabot GG, Bruno R, Bissery MC, Bayssas M, Klink-Alakl M, Clavel M, Catimel G Phase I and pharmacology study of intoplicine (RP 60475; NSC 645008), a novel topoisomerase I and II inhibitor, in cancer patients. Anticancer Drugs. 7:1996;166-174.
39. Fan Y, Weinstein JN, Kohn KW, Shi LM, Pommier Y Molecular modeling studies of the DNA-topoisomerase I ternary cleavable complex with camptothecin. J Med Chem. 41:1998;2216-2226. This paper describes a model of the anticancer drug camptothecin bound to DNA in the context of the modeled positions of residues Asn722 and Tyr723 (in a 3′ phosphotyrosine linkage with the DNA) of human topoisomerase I.
40. Pommier Y, Kohlhagen G, Kohn KW, Leteurtre F, Wani MC, Wall ME Interaction of an alkylating camptothecin derivative with a DNA base at topoisomerase I-DNA cleavage sites. Proc Natl Acad Sci USA. 92:1995;8861-8865.